Mutated or dysregulated transcription factors represent a unique class of drug targets that
mediate aberrant gene expression, including blockade of differentiation and cell death gene …

Runt-related transcription factor 1 (RUNX1) is frequently involved in the progression of acute
leukemia. However, emerging and discoverable RUNX1 somatic mutations, RUNX1 …

Acute myeloid leukemia (AML) is the most common diagnosed leukemia. In older adults,
AML confers an adverse outcome,. AML originates from a dominant mutation, then acquires …

Proteolysis targeting chimeras (PROTACs) are heterobifunctional small molecules that
utilize the ubiquitin proteasome system (UPS) to degrade proteins of interest (POI) …

Recognition that germline mutations can predispose individuals to blood cancers, often
presenting as secondary leukemias, has largely been driven in the last 20 years by studies …

The majority of RUNX1 mutations in acute myeloid leukemia (AML) are missense or deletion-
truncation and behave as loss-of-function mutations. Following standard therapy, AML …

Despite FDA approval of nine new drugs for patients with acute myeloid leukemia (AML) in
the United States over the last 4 years, AML remains a major area of unmet medical need …

Hereditary platelet disorders (HPDs) are a group of blood disorders with variable severity
and clinical impact. Although phenotypically there is much overlap, known genetic causes …

Monotherapy with Menin inhibitor (MI), eg, SNDX-5613, induces clinical remissions in
patients with relapsed/refractory AML harboring MLL1-r or mtNPM1, but most patients either …

Simple Summary The study discusses the potential of targeting transcription factors (TFs) for
cancer therapy and provide a systematic classification of various types of TFs involved in the …